Evaluation of prostate specific antigen in the prognosis of patients with advanced prostate cancer
Keywords:
PSA, Advanced prostate cancer, Maximum blockage androgen, Prognostic factorsAbstract
OBJECTIVE: To evaluate the survival rate of patients with advanced prostate cancer in a univariate form, according to the preoperative and first postoperative determination of PSA levels. MATERIALS AND METHODS: From February 1987 to June 1995, 92 patients were submitted to maximum blockage androgen (subcapsular and antiandrogen orchiectomy), independent of clinical symptons shown upon admission to the Cancer Hospital. The antiandrogens (ciproterone acetate and flutamide) were administered until the patient present progression of the disease. RESULTS: The age of patients varied from 44 to 89, with a median of 70 years old. In the 6th, 36th and 60th months the global survival rate was 80%, 38% and 20%, respectively. The preoperative PSA ranged from 2 to 4017 ng/ml, with a median of 98 ng/ml (98% had PSA greater than or equal to 10 ng/ml). The first postoperative PSA ranged from 1 to 3840 ng/ml, with a median of 20 ng/ml. There was a tendency towards a better survival rate only in patients with initial PSA from 2 to 99 ng/ml (p=0.06745). The survival rate of patients at 36 months after the initial total blockage androgen, with first PSA level from 1 to 4, 5 to 49 and over 49 ng/ml was 72%, 48% and 8%, respectively (p=0.00004). In the final examination, 34 (37%) patients were considered stable and 58 (63%) had disease progression. CONCLUSION: The PSA determination performed on the 30th postoperative day is important in the evaluation of advanced prostate cancer prognosis.
Downloads
References
Wang MC, Valenzuela LA, Murphy GP, Chu TM. Purification of human prostatic specific antigen. Invest Urol 1979;17:159-63.
Ercole CJ, Lange PH, Mathisen M, Chiou RK, Reddy PK, Vessella RL. Prostate specific antigen and prostatic acid phosphatase in the monitoring and staging of patients with prostatic cancer. J Urol 1987;138:1181-4.
Miller JI, Ahmann FR, Drach GW, Emerson SS, Bottaccini MR. The clinical usefulness of serum prostate specific antigen after hormonal therapy of metastatic prostate cancer. J Urol 1992;147:956-61.
Dupont A, Cusan L, Gomez J, Thibeault M, Tremblay M, Labrie F. Prostate specific antigen and prostatic acid phosphatase for monitoring therapy of carcinoma of the prostate. J Urol 1991;146:1064-9.
Oesterling JE. Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 1991;45:907-23.
Haim M, Eber P, Todd B, Zwaag R, Soloway MS. Prognostic significance of changes in prostate-specific markers after endocrine treament of stage D2 prostatic cancer. Cancer 1992;70:2302-6.
Ahmann FR, Schifman RB. Prospective comparison between serum monoclonal prostate specific antigen and acid phosphatase measurements in metastatic prostatic cancer. J Urol 1987;137:431-5.
Hermanek P, Sobin LH, editors. Classification of malignant tumours of union against cancer: prostate cancer. 4th edition. Berlin: Springer-Verlag 1987;124-6.
Slack NH, Murphy GP and participants in the National Prostatic Cancer Project: criteria for evaluating patient responses to treatment modalites for prostatic cancer. Urol Clin N Amer 1984;11:337-41.
Campos-Filho N, Franco ELF. Microcomputer-assisted multivariate survival analysis using Cox's proportional hazards regression model. Comput Methods Prog Biomed 1990;31:81-5.
Campos-Filho N, Franco ELF. Microcomputer-assisted multivariate survival analysis using Kaplan-Meier life table estimators. Methods Programs Biomed 1988;27:223-6.
Huggins C, Stevens RE, Hodges CV. Studies on prostatic cancer II: the effects of castration on advanced carcinoma of the prostate gland. Arch Surg 1941;43:207-11.
Chapman JP. Comparison of testosterone and LH values in subcapsular vs total orchiectomy patients. Urology 1987;30:27-30.
Smith PH. Deferred therapy in patients with advanced disease. Cancer 1993;71:1074-8.
McLeod DG, Crawford ED, Blumenstein BA, Eisenberg MA, Dorr FA. Controversies in the treatment of metastatic prostate cancer. Cancer 1992;70:324-8.
Myrtle JK, Klimley PG, Ivor LP, Bruni JF. Clinical utility of prostate-specific antigen (PSA) in the management of prostate cancer. In: Advances in cancer diagnosis. San Diego 1986;p.1-6.
Chybowsky FM, Keller JJL, Bergstrahl EJ, Oesterling JE. Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: prostate specific antigen is superior to all other clinical parameters. J Urol 1991;145:313-8.
Leo ME, Bilhartz DL, Bergstrahl EJ, Oesterling JE. Prostate specific antigen in hormonally treated stage D2 prostate cancer: is it always an accurate indicator of disease status? J Urol 1991;145:802-6.
Keillor JS, Aterman K. The response of poorly differentiated prostatic tumors to staining for prostate antigen and prostatic acid phosphatase: a comparative study. J Urol 1987;137:894-7.
Stamey TA, Kabalin JN, Ferrari M, Yang N. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate IV. Anti-androgen treated patients. J Urol 1989;141:1088-92.
Petros JA, Andriole GL. Serum PSA after antiandrogen therapy. Urol Clin North Am 1993;20:(40):749-56.
Janknegt RA, Abbou CC, Bartoletti R. Orchiectomy and nilutamide or placebo as treatment of metastatic prostatic cancer in a multinational double-blind randomized trial. J Urol 1993;149:77-81.
